Navigation Links
Epizyme, Inc. to Be Added to NASDAQ Biotechnology Index (NBI) and NASDAQ Global Select Market
Date:12/20/2013

CAMBRIDGE, Mass., Dec. 20, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective before market open on December 23, 2013.  Epizyme also announced that its common stock will be transferred to the NASDAQ Global Select Market effective January 2, 2014.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Index is the basis for the iShares NASDAQ Biotechnology Index(SM) Fund (Nasdaq: IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index.  In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges.

The NASDAQ Global Select Market is the top listing tier for NASDAQ companies, with the highest initial listing standards in the world.

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.


'/>"/>
SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Epizyme, Inc. Provides Third Quarter 2013 Financial Results and Corporate Update
2. Epizyme, Inc. Reports Second Quarter 2013 Financial Results
3. Global Bulk Molding Compounds Market and China LOW-E Glass Analysis in New Research Added to DeepResearchReports.com
4. Welcome guests: Added molecules allow metal-organic frameworks to conduct electricity
5. MarketPublishers.com Added New Report on Thujone, (A + B)(SG) (CAS 2867-05-2) Market to Its Catalogue
6. MarketPublishers.com Added New Report on Silicon Nitride (CAS 12033-89-5) Market to Its Catalogue
7. MarketPublishers.com Added New Report on Chlorinated Polypropylene (CAS 68442-33-1) Market to Its Catalogue
8. MarketPublishers.com Added New Report on Sodium Nitrite (CAS 7632-00-0) Market to Its Catalogue
9. MarketPublishers.com Added New Report on Levocarnitine (CAS 541-15-1) Market to Its Catalogue
10. MarketPublishers.com Added New Report on Hydroxyethyl Starch (CAS 9005-27-0) Market to Its Catalogue
11. MarketPublishers.com Added New Report on Povidone Iodine (CAS 25655-41-8) Market to Its Catalogue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... their findings on what they believe could be a new and helpful biomarker ... new research. Click here to read it now. , Biomarkers are ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
Breaking Biology News(10 mins):